Literature DB >> 14519149

Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects.

J de Kluijver1, K Grünberg, D Pons, E P A de Klerk, C R Dick, P J Sterk, P S Hiemstra.   

Abstract

BACKGROUND: Exacerbations of asthma are often associated with rhinovirus (RV)-induced common colds. During experimental RV-infection in healthy subjects, increased levels of the pro-inflammatory mediator IL-1beta and the anti-inflammatory IL-1 receptor antagonist (IL-1ra) have been found in nasal lavage.
OBJECTIVE: We postulated that the balance between nasal pro- and anti-inflammatory mediator expression is disturbed in asthma, resulting in more extensive inflammation following RV-exposure in asthma.
METHODS: We determined IL-1ra, IL-1beta, and IL-8 in nasal lavages (days -2, 3, and 6) of non-asthmatics and asthmatics (with and without pre-treatment with the inhaled steroid budesonide) before and after experimental RV16-infection (days 0 and 1).
RESULTS: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035). A small, but significant, increase in IL-1ra was only observed in the budesonide-treated asthmatics (P=0.047). At baseline, IL-1ra levels were significantly higher in the non-asthmatics than in the placebo-treated asthmatics (P=0.017).
CONCLUSION: These results demonstrate differences between non-asthmatic and asthmatic subjects in the basal levels of nasal cytokines and their inhibitors, and in the effect of experimental RV-infection on these levels. The results indicate that RV may enhance inflammation more markedly in asthmatics, and suggest that this may in part be explained by lower IL-1ra levels. In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519149     DOI: 10.1046/j.1365-2222.2003.01770.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  23 in total

1.  Rhinovirus infection of allergen-sensitized and -challenged mice induces eotaxin release from functionally polarized macrophages.

Authors:  Deepti R Nagarkar; Emily R Bowman; Dina Schneider; Qiong Wang; Jee Shim; Ying Zhao; Marisa J Linn; Christina L McHenry; Babina Gosangi; J Kelley Bentley; Wan C Tsai; Umadevi S Sajjan; Nicholas W Lukacs; Marc B Hershenson
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

2.  Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin.

Authors:  Deepti R Nagarkar; Julie A Poposki; Michael R Comeau; Assel Biyasheva; Pedro C Avila; Robert P Schleimer; Atsushi Kato
Journal:  J Allergy Clin Immunol       Date:  2012-05-26       Impact factor: 10.793

3.  Inflammasome activation is required for human rhinovirus-induced airway inflammation in naive and allergen-sensitized mice.

Authors:  Mingyuan Han; J Kelley Bentley; Charu Rajput; Jing Lei; Tomoko Ishikawa; Caitlin R Jarman; Julie Lee; Adam M Goldsmith; William T Jackson; Mark J Hoenerhoff; Toby C Lewis; Marc B Hershenson
Journal:  Mucosal Immunol       Date:  2019-05-15       Impact factor: 7.313

Review 4.  Bugs and asthma: a different disease?

Authors:  Dawn C Newcomb; R Stokes Peebles
Journal:  Proc Am Thorac Soc       Date:  2009-05-01

5.  CXCR2 is required for neutrophilic airway inflammation and hyperresponsiveness in a mouse model of human rhinovirus infection.

Authors:  Deepti R Nagarkar; Qiong Wang; Jee Shim; Ying Zhao; Wan C Tsai; Nicholas W Lukacs; Uma Sajjan; Marc B Hershenson
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

6.  Nasal lavage VEGF and TNF-α levels during a natural cold predict asthma exacerbations.

Authors:  D M Manthei; E A Schwantes; S K Mathur; A G Guadarrama; E A Kelly; J E Gern; N N Jarjour; L C Denlinger
Journal:  Clin Exp Allergy       Date:  2014-12       Impact factor: 5.018

7.  IL-1β prevents ILC2 expansion, type 2 cytokine secretion, and mucus metaplasia in response to early-life rhinovirus infection in mice.

Authors:  Mingyuan Han; Tomoko Ishikawa; Jennifer R Bermick; Charu Rajput; Jing Lei; Adam M Goldsmith; Caitlin R Jarman; Julie Lee; J Kelley Bentley; Marc B Hershenson
Journal:  Allergy       Date:  2020-03-10       Impact factor: 13.146

8.  Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection.

Authors:  Clare A Stokes; Saila Ismail; Emily P Dick; Julie A Bennett; Sebastian L Johnston; Michael R Edwards; Ian Sabroe; Lisa C Parker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

Review 9.  Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Authors:  Abhijit Chakraborty; Stacey Tannenbaum; Christiane Rordorf; Philip J Lowe; David Floch; Hermann Gram; Sandip Roy
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 10.  Viruses exacerbating chronic pulmonary disease: the role of immune modulation.

Authors:  Aran Singanayagam; Priya V Joshi; Patrick Mallia; Sebastian L Johnston
Journal:  BMC Med       Date:  2012-03-15       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.